153 related articles for article (PubMed ID: 32658070)
1. Evaluation of Pathologic Response on Overall Survival After Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma.
Sell NM; Lee GC; Fernández-Del Castillo C; Ferrone CR; Warshaw AL; Hong TS; Blaszkowsky LS; Lillemoe KD; Qadan M
Pancreas; 2020 Aug; 49(7):897-903. PubMed ID: 32658070
[TBL] [Abstract][Full Text] [Related]
2. Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer?
He J; Blair AB; Groot VP; Javed AA; Burkhart RA; Gemenetzis G; Hruban RH; Waters KM; Poling J; Zheng L; Laheru D; Herman JM; Makary MA; Weiss MJ; Cameron JL; Wolfgang CL
Ann Surg; 2018 Jul; 268(1):1-8. PubMed ID: 29334562
[TBL] [Abstract][Full Text] [Related]
3. Does Neoadjuvant Chemotherapy Change the Role of Regional Lymphadenectomy in Pancreatic Cancer Survival?
Macedo FI; Picado O; Hosein PJ; Dudeja V; Franceschi D; Mesquita-Neto JW; Yakoub D; Merchant NB
Pancreas; 2019 Jul; 48(6):823-831. PubMed ID: 31210664
[TBL] [Abstract][Full Text] [Related]
4. Recurrence in Patients Achieving Pathological Complete Response After Neoadjuvant Treatment for Advanced Pancreatic Cancer.
Blair AB; Yin LD; Pu N; Yu J; Groot VP; Rozich NS; Javed AA; Zheng L; Cameron JL; Burkhart RA; Weiss MJ; Wolfgang CL; He J
Ann Surg; 2021 Jul; 274(1):162-169. PubMed ID: 32304375
[TBL] [Abstract][Full Text] [Related]
5. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
[TBL] [Abstract][Full Text] [Related]
6. Nodal downstaging as a treatment goal for node-positive pancreatic cancer.
Portuondo JI; Massarweh NN; Zhang Q; Chai CY; Tran Cao HS
Surgery; 2019 Jun; 165(6):1144-1150. PubMed ID: 30745009
[TBL] [Abstract][Full Text] [Related]
7. Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
Hashemi-Sadraei N; Gbolahan OB; Salfity H; O'Neil B; House MG; Shahda S
Am J Clin Oncol; 2018 Oct; 41(10):982-985. PubMed ID: 28968257
[TBL] [Abstract][Full Text] [Related]
8. Vascular resection during pancreatectomy for pancreatic head cancer: A technical issue or a prognostic sign?
Belfiori G; Fiorentini G; Tamburrino D; Partelli S; Pagnanelli M; Gasparini G; Castoldi R; Balzano G; Rubini C; Zamboni G; Crippa S; Falconi M
Surgery; 2021 Feb; 169(2):403-410. PubMed ID: 32912782
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic ductal adenocarcinoma: tumour regression grading following neoadjuvant FOLFIRINOX and radiation.
Neyaz A; Tabb ES; Shih A; Zhao Q; Shroff S; Taylor MS; Rickelt S; Wo JY; Fernandez-Del Castillo C; Qadan M; Hong TS; Lillemoe KD; Ting DT; Ferrone CR; Deshpande V
Histopathology; 2020 Jul; 77(1):35-45. PubMed ID: 32031712
[TBL] [Abstract][Full Text] [Related]
10. Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes.
Harrison JM; Wo JY; Ferrone CR; Horick NK; Keane FK; Qadan M; Lillemoe KD; Hong TS; Clark JW; Blaszkowsky LS; Allen JN; Castillo CF
Ann Surg Oncol; 2020 May; 27(5):1400-1406. PubMed ID: 31758284
[TBL] [Abstract][Full Text] [Related]
11. Total neoadjuvant therapy is associated with improved overall survival and pathologic response in pancreatic adenocarcinoma.
Villano AM; O'Halloran E; Goel N; Ruth K; Barrak D; Lefton M; Reddy SS
J Surg Oncol; 2022 Sep; 126(3):502-512. PubMed ID: 35476892
[TBL] [Abstract][Full Text] [Related]
12. The association of adjuvant therapy with survival at the population level following pancreatic adenocarcinoma resection.
Kagedan DJ; Raju RS; Dixon ME; Shin E; Li Q; Liu N; Elmi M; El-Sedfy A; Paszat L; Kiss A; Earle CC; Mittmann N; Coburn NG
HPB (Oxford); 2016 Apr; 18(4):339-47. PubMed ID: 27037203
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN).
McMillan MT; Lewis RS; Drebin JA; Teitelbaum UR; Lee MK; Roses RE; Fraker DL; Vollmer CM
Cancer; 2016 Feb; 122(4):521-33. PubMed ID: 26587698
[TBL] [Abstract][Full Text] [Related]
14. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis.
Zhao Q; Rashid A; Gong Y; Katz MH; Lee JE; Wolf R; Balachandran A; Varadhachary GR; Pisters PW; Wang H; Gomez HF; Abbruzzese JL; Fleming JB; Wang H
Ann Diagn Pathol; 2012 Jan; 16(1):29-37. PubMed ID: 22050964
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis.
Mokdad AA; Minter RM; Zhu H; Augustine MM; Porembka MR; Wang SC; Yopp AC; Mansour JC; Choti MA; Polanco PM
J Clin Oncol; 2017 Feb; 35(5):515-522. PubMed ID: 27621388
[TBL] [Abstract][Full Text] [Related]
16. The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer patients: a retrospective analysis.
Amin S; Baine M; Meza J; Lin C
BMC Cancer; 2020 Jun; 20(1):538. PubMed ID: 32517661
[TBL] [Abstract][Full Text] [Related]
17. Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma.
Cloyd JM; Wang H; Egger ME; Tzeng CD; Prakash LR; Maitra A; Varadhachary GR; Shroff R; Javle M; Fogelman D; Wolff RA; Overman MJ; Koay EJ; Das P; Herman JM; Kim MP; Vauthey JN; Aloia TA; Fleming JB; Lee JE; Katz MHG
JAMA Surg; 2017 Nov; 152(11):1048-1056. PubMed ID: 28700784
[TBL] [Abstract][Full Text] [Related]
18. Survival Trends for Resectable Pancreatic Cancer Using a Multidisciplinary Conference: the Impact of Post-operative Chemotherapy.
Syed AR; Carleton NM; Horne Z; Dhawan A; Bedi G; Kochhar G; Morrissey S; Williams H; Atkinson D; Schiffman S; Monga D; Lupetin A; Kirichenko A; Mitre M; Dhawan M; Kulkarni A; Thakkar S
J Gastrointest Cancer; 2020 Sep; 51(3):836-843. PubMed ID: 31605289
[TBL] [Abstract][Full Text] [Related]
19. Prolonged Neoadjuvant Therapy for Locally Advanced Pancreatic Cancer.
Eguchi H; Yamada D; Iwagami Y; Gotoh K; Kawamoto K; Wada H; Asaoka T; Noda T; Takeda Y; Tanemura M; Sakai D; Satoh T; Kudo T; Isohashi F; Mori M; Doki Y
Dig Surg; 2018; 35(1):70-76. PubMed ID: 28482348
[TBL] [Abstract][Full Text] [Related]
20. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]